With the race now officially on to open the first medical marijuana (MMJ) dispensaries in Nevada, just a month after Nevada Pure broke ground on the state’s first big secure farming operation in east Las Vegas, anticipation is running high across the state regarding the upcoming 2016 general election ballot initiative that may legalize recreational use. Given that Colorado pulled in over $700 million last year and is currently on track to break $1 billion in annual revenues by 2016, according to projections based on state Department of Revenue data, and that a poll back in 2013 already showed 54 percent of Nevadans favored legalization, the MMJ market in Nevada could very quickly get a whole lot bigger next year.

Good news for fast growing biopharma company GrowBLOX Sciences (OTC: GBLX), whose advanced cultivation technology systems ensures maximized genetic potential of selectively propagated strains that ultimately contain more active ingredients per pound than is achieved with other cultivation methods. As of June 15th, the company has secured a $1.75 million funding commitment from Pacific Leaf Ventures to build out its MME (Medical Marijuana Establishment) known as The Cultivation Lab through a deal that includes key, highly recognizable cannabis brand names, as well as proprietary cultivation and extraction methods.
This state of the art facility, situated in a 28,000 ft.² warehouse, is set to produce well over 4000 lbs of high-grade cannabis per annum.

With dispensaries cropping up all over the place in Nevada amid a dearth of grow operations, the state faces a supply shortfall, and GBLX is now shrewdly positioned for a mid-Q4 completion of its cultivation facility. This facility’s purpose is to produce high profile strains and products that should appeal directly to MME cardholder patients in the state, as well as in neighboring Arizona and California markets since Nevada is unique to allow medical marijuana patient cards from other states to be recognized.
In addition to the projected medical cannabis market, California currently has a legalization proposal on the ballot for 2016, just like Nevada. Recent consumption demand estimates for California by NORML run in the neighborhood of 2 million pounds per year, a retail market potentially worth as much as around $9 billion at the average cost of $10.00 plus per gram of high quality strains. Even at the average cost per gram of medium quality strains, California represents a potential $6 billion retail market, or half that if we low-ball the cost per gram figure.

The total nationwide cannabis market is around $2.7 billion as of last year according to ArcView Market Research and it grew 70 percent or more between 2013 and 2014. With a 2019 projection of around $10.8 billion, which would be a whopping 300 percent increase, sector operators like GrowBLOX Sciences stand to see considerable upside as things progress further. ArcView’s projections are largely based on an extension of the clear trend of other states following Colorado into the tax revenue generation bonanza, but should not be taken as speculation. Indeed, with multiple states currently moving to either roll back restrictions, or pass measures to open up even recreational use, even as Canada’s Supreme Court handed down a landmark ruling which stipulates that patients can consume their medicine however they want, including in edible or oil form, the future upside for the MMJ sector in North America is tantalizing to say the least.

The company’s initial Nevada location for its retail footprint roll out, branded The Apothecary, with an attractive “compassionate cross ” logo that is easily recognizable by the green cross merged with the heart symbol. Combining the approachable and trustworthy aesthetics of a clean, minimalistic and clinical-feeling interior, with sophisticated, yet simplified biometrically-driven patient verification, The Apothecary layout features a security foyer for initial patient processing, waiting and consultation rooms, as well as a retail display area, and secure payment section. This same model will serve as the template for future retail locations and should help to establish a sense of trust and security among consumers. A clean, safe and above all comfortable experience was the goal in designing The Apothecary, and the company’s initial store will be located just across the street and slightly north of a Walgreens, four miles north of the major medical district in southwest Las Vegas’ Spring Valley area.

By putting together a sophisticated and streamlined, biometrically-driven front end to handle registration, consultation and procurement, The Apothecary will be able to deliver a stress-free and quick processing experience to patients, all within an enviably safe environment; something which should set the company apart immediately and make them a preferred solution for consumers.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

The Aristocrat Group Corp. is a brand management company specializing in the discovery and promotion of unique brands with mass market appeal. The company strategizes to capitalize on unprecedented brand-building opportunities, and is working to build a portfolio of successful brands to compete alongside industry leaders like Moet Hennessy, Louis Vuitton, Diageo PLC, and Brown-Forman Corp.

Luxuria Brands, an ASCC subsidiary, is tasked with brand management and sustainability, specifically in the beverage alcohol sector, where the company will develop and market brands using strategic, cross-cultural branding initiatives that engage businesses and consumers. Vodka boasts a significantly high market share, accounting for 25 percent of all distilled spirits sold in the United States. What this means for ASCC investors is that they have a remarkable chance to capitalize on a proven commodity and business model for distribution.

To this accord, ASCC’s current portfolio of premium luxury goods brands includes top-shelf distilled spirits like RWB Vodka, an ultra-premium handcrafted spirit that has already met remarkable success, including multiple awards. The market for vodka is estimated to be at almost 60 million cases per year in the United States alone, and beverages priced at a premium level are garnering top-dollar returns for businesses and investors. Strategizing to capitalize on this powerful sector, ASCC plans to debut a second lifestyle vodka brand later this year.

ASCC’s experienced and visionary management team is committed to creating a solid foundation for innovative technologies and models, ranging from mobile couponing to social engagement, that drive business forward. Building on its established presence in the lucrative beverage alcohol sector, ASCC is emerging as a trusted platform where fledgling ideas turn into commercial successes.

For more information, visit www.aristocratgroupcorp.com

Let us hear your thoughts: The Aristocrat Group Corp. Message Board

WRIT Media Group is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and “retro” video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content.

For more information, visit www.writmediagroup.com

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

Today before the opening bell, One World Holdings’ subsidiary announced that it will conduct a live stockholders conference call next week on Wednesday, July 1 at 11:30 AM ET.

The primary speakers for this call will be Joanne Melton, One World Holdings CEO; and Stacey McBride-Irby, creator of the Prettie Girls! doll line. The call will also include Trent T. Daniel, Founder of The One World Doll Project, who will be moderating the call.

Because a large number of investors are expected to dial-in, the call will be listen-only. Those who wish to join should dial in at 712-432-0075 pin 278621# no later than 11:28 AM ET on Wednesday, July 1. The call will last no longer than 45 minutes and a recording will be posted to the company website after the call.

For more information on The One World Doll Project subsidiary, visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

Pulse Beverage Corp. is an emerging beverage company that provides consumers with high-quality, healthy alternatives to traditional refreshment options. Since launching its first product, Natural Cabana® Lemonade, in 2012, the company has rapidly expanded its product line to include its flagship PULSE® brand of nutritional beverages, limeade and coconut water. Moving forward, Pulse will look to continue to develop its network of retail outlets, supermarkets and convenience stores in order to become a market leader in the nutritional and functional beverage categories.

In recent years, the functional beverage market in the United States has recorded steady growth, providing Pulse with a significant opportunity to continue expanding its market share in the years to come. According to a report by Statista, retail sales of functional beverages in the U.S. accounted for approximately $16 billion in 2010, and that figure is expected to grow by more than 16 percent by the end of this year. For Pulse, this consumer interest could translate into big returns.

In the first quarter of 2015, the company’s net sales rose by nearly 25 percent, as compared to the same period in 2014. These results were driven by vast expansion to Pulse’s retail distribution network, which now includes some of the world’s biggest retail chains. In particular, the company secured manager approval status with Walmart for its Natural Cabana Lemonade, with an active presence in more than 300 stores to date, as well as listings in 50 Wegmans mega-stores and nearly 500 7-Eleven stores throughout Canada.

“We achieved significant operational progress during the first quarter of 2015,” Bob Yates, chief executive officer of Pulse, stated in a news release. “We have spent 3.5 years in establishing our comprehensive nationwide and international distribution system. We believe this… will lead to a breakout year in 2015.”

Since launching its first product, Pulse has secured more than 20,000 listings for its lemonades and limeades, in addition to more than 5,000 listings for its coconut waters. This month, the company plans to expand upon this progress by introducing its proven lemonade product to the Mexico market, establishing another channel for retail growth in the future.

For prospective shareholders, the rapid expansion of Pulse’s distribution network, the company’s improved financial results and the growing demand of the functional beverage market combine to make Pulse an intriguing investment opportunity in the current market.

For more information, visit www.pulsebeverage.com

Discovery Ventures, Inc. (OTCQX: DTVMF) is an exploration and development stage mining company focused on the WillaMax gold project in southeast British Columbia, Canada. The Willa property is highly developed, with current measured and indicated resources of over 758,000 metric tons grading 6.67 grams of gold per unit. The Max project, which is located approximately 135 kilometers away from the Willa project, features the necessary infrastructure to effectively process the company’s mined resources, providing Discovery with financially-viable means of production moving forward.

Earlier this month, the company announced the results from the recently completed test work program on the Willa Mine. According to the news release, the test, which was conducted by MetSolve Labs, found the metallurgical recoveries from the site’s intermediate grade mineral samples to be greater than indicated by historical records. In the weeks to come, the company will look to build on these strong results as testing on the site’s high grade and sub-grade samples begins.

“We are encouraged by these results,” Akash Patel, president and chief executive officer of Discovery, stated in a news release. “These findings signal a positive outlook for our company’s WillaMax project’s production potential.”

The Willa property has been explored sporadically since 1893. In 2003, a mineral resource calculation was completed on the property based on historical drilling results. Two years later, a preliminary mine design and schedule was developed, but the prevailing metal prices didn’t yield a sufficient return to make production a feasible option. However, an increase in gold prices of approximately 280 percent in the last decade has effectively limited this concern, making the property a potentially lucrative opportunity for Discovery in the future.

In recent weeks, Discovery took a major step toward production by entering into a definitive agreement with investor Dan Omeniuk for up to $7 million in convertible credit. With the proceeds from these credit facilities, the company will look to rapidly advance.

“We are very excited to have Dan Omeniuk join the Discovery team,” continued Patel. “Dan brings a wealth of knowledge and entrepreneurship success and we are confident in his ability to spearhead and advance the WillaMax gold project.”

For more information, visit www.discoveryventuresinc.com

ImmunoCellular Therapeutics, Ltd. is a clinical stage biotechnology company developing immune-based therapies for the treatment of brain and other cancers. The company’s leading product candidate, ICT-107, is a vaccine that targets antigens associated with glioblastoma multiforme (GBM), the most common and lethal form of brain cancer. In recent weeks, ImmunoCellular has made progress toward the initiation of phase III clinical trials for the drug candidate, announcing an agreement with Caladrius Biosciences, Inc. for manufacturing services, including processing, packaging, labelling, quality control testing, release, shipping and storage. Building on this progress, patient enrollment for the trial is expected to begin by the early fourth quarter of this year.

When completed, ICT-107 will address a critically underserved market within the medical industry. According to a report by the American Cancer Society, an estimated 10,000 new patients are diagnosed with GBM in the United States each year. Despite advances in surgery, radiation and chemotherapy, recurrence is a near certainty and the median survival time for newly diagnosed GBM patients in only 14.6 months. In ImmunoCellular’s phase II trials for ICT-107, results suggested potential for greatly increased chances of long-term survival when treated with the company’s novel vaccine.

“We believe that we are on track to initiate the ICT-107 phase III trial in the late third quarter or fourth quarter of this year, following completion of the special protocol assessment process with the FDA and finalization of agreements with cancer cooperative groups and our contract research organization, which will manage the trial,” Andrew Gengos, chief executive officer of ImmunoCellular, stated in a news release. “We believe there is significant value in ImmunoCellular, given the breadth of our platforms and our preclinical and clinical assets, led by ICT-107.”

The company’s product pipeline also includes a dendritic cell-based vaccine that targets CD133, an antigen commonly associated with cancer stem cells. This candidate, known as ICT-121, is nearing the start of phase I clinical trials, with patient enrollment actively underway.

Moving forward, ImmunoCellular is in position to realize its corporate goal of becoming an industry-leading commercial-stage cancer immunotherapy company. Its pipeline of commercially attractive assets could provide the company with the opportunity to achieve sustainable returns while effectively transforming the treatment of cancer.

For more information, visit www.imuc.com

Breitling Energy is a growing energy company engaged in the exploration and development of high probability onshore oil and gas properties. The company’s current portfolio of projects includes leaseholds in the Permian Basin of Texas and the Mississippi oil window of southern Kansas and northern Oklahoma, as well as non-operating investments in Texas, North Dakota, Oklahoma and Mississippi. Leveraging a dual-focused growth strategy, Breitling is expanding its impact on the industry through a combination of active drilling efforts and a growing network of non-operating and royalty interests. This approach allows Breitling to promote sustained growth while diversifying its mineral interest portfolio, effectively limiting operational risk on a well-by-well basis.

In recent weeks, Breitling has achieved major milestones through both portions of its growth strategy. First, the company announced that a new well at its non-operated working interest in Sterling County, Texas, reached total depth and initiated completion operations. Then, Breitling announced the start of fracking operations at its leasehold in the Permian Basin. Despite slumping oil prices, which appear to be slowly recovering following the dramatic decrease during the first quarter of this year, the company’s management is confident that it can realize sustainable returns through these efforts to increase production.

“It’s not so much about price for us as it is optimization,” Chris Faulkner, chairman and chief executive officer of Breitling, stated in a news release. “Our lease in the Permian Basin allows us to be efficient, and we will continue developing the field without debt, which gives us the added confidence to move forward with the company plan we outlined in our first year.”

The company’s Permian Basin leasehold could provide it with a formidable platform to realize substantial growth in the coming years. According to a report by the Railroad Commission of Texas, the region has been a hotbed for the oil and gas industry in recent years. From 2005 to 2012, oil production increased by over 23 percent, climbing to approximately 312 million barrels in the final year of the period.

Moving forward, Breitling appears to be in a strong position to work toward its primary goal of increasing shareholder value through a combination of exploration, drilling and proven engineering extraction practices. For prospective shareholders, the company’s recent progress and the ongoing recovery of global crude oil prices combine to make Breitling an intriguing investment opportunity.

For more information, visit www.breitlingenergy.com

Cibolan Gold is an aggressive junior mining exploration and development company actively pursuing the reopening of its Independence gold and silver mining project in the Battle Mountain Mining District of Nevada. The company’s project, which is located adjacent to the multi-billion dollar Phoenix gold mine of the Newmont Mining Corporation (NEM), contains approximately one million ounces of gold and four million ounces of silver in the measured, indicated and inferred categories, providing Cibolan with a significant opportunity to realize strong returns moving forward.

In April, Cibolan released the results of a preliminary review of the production potential of its Independence project. According to the study, the project has the potential to provide four to five million tons containing more than 200,000 ounces of gold in a financially-viable manner. In particular, the evaluation highlighted three high-grade target areas that could allow the company to expand upon the availability of gold in the near surface mineralized material. As a result, Cibolan plans to focus on the rapid expansion of these new zones in the coming months.

“This is great news for shareholders as we now have a more clear understanding of how the mineralization is controlled by the various faults existing on the property,” Daniel J. Forbush, president and chief executive officer of Cibolan, stated in a news release. “I feel that this development makes Cibolan a ‘must watch’ company for gold focused investors.”

The Independence mine has been in production intermittently since 1938. Historically, the plot has produced approximately 11,000 ounces of gold, as well as about 750,000 ounces of silver. With its technical review of the project now complete, Cibolan moves one step closer to building upon these production statistics. In April, the company announced an agreement with Envirotech Drilling LLC to begin drilling operations in the project’s most promising sites.

For prospective investors, Cibolan’s recent progress toward production makes it an interesting opportunity in the months to come. Look for the company to continue to make strides toward achieving sustainable returns from its Independence project moving forward.

For more information, visit www.nevada-goldmine.com

Aethlon Medical, Inc. (OTCQB: AEMD) creates affinity biofiltration devices to treat life-threatening diseases. The company’s leading therapeutic candidate, the Aethlon Hemopurifier®, is a broad-spectrum therapeutic strategy developed to address drug resistant viral pathogens. To date, the device, which was recently named among ‘The 11 Most Remarkable Advances in Healthcare’ by Time Magazine, has been successfully administered to individuals infected with Ebola virus, hepatitis C and the human immunodeficiency virus (HIV), demonstrating the immense potential for the company’s novel treatment device moving forward.

In addition to validating the treatment of some of the world’s deadliest pathogens, Aethlon is also investigating the use of its Hemopurifier therapy to capture tumor-derived exosomes, which have been shown to promote cancer progression. When complete, this application will address a substantial demand within the cancer treatment market. In April, the company took a significant step toward the eventual commercialization of its proprietary therapeutic candidate by entering into a clinical trial agreement with the University of California, Irvine to establish baseline exosome levels and monitor their associations with various types of cancers. The results of this study will help direct future clinical investigations.

The company’s current product pipeline is built upon its revolutionary Aethlon ADAPT™ system, which is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that target the selective clearance of harmful agents from the circulatory system. In addition to the Hemopurifier, Aethlon is currently utilizing this system to develop HER2osome™ to target HER2+ breast cancer and a novel medical device to reduce the incidence of sepsis in combat-injured soldiers, which is sponsored by the Defense Advanced Research Projects Agency (DARPA).

Exosome Sciences, Inc., Aethlon’s majority-owned subsidiary, is supporting this product development through the creation of its groundbreaking diagnostic tool, ELLSA™. This device provides greater exosome detection sensitivity than any other product currently on the marketplace. With ELLSA, Aethlon gains enhanced ability to identify and quantify the underlying presence of exosomes in a wide variety of relevant treatment applications.

As Aethlon continues to develop its unique pipeline of therapeutic solutions, the potential for market growth upon commercialization is effectively limitless. With a potential uplisting to the NASDAQ Capital Markets currently pending approval, it is an exciting time for shareholders of this company.

For more information, visit www.aethlonmedical.com